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Abstract 
Background: Third‑generation cephalosporins (3GCs) are recommended for empirical antibiotic therapy of commu‑
nity‑acquired pneumonia (CAP) in patients requiring ICU admission. However, their extensive use could promote the 
emergence of extended‑spectrum beta‑lactamases‑producing Enterobacteriaceae. Our aim was to assess whether the 
use of 3GCs in patients with CAP requiring ICU admission was justified.
Methods:  We assessed all patients with CAP who required ICU admission during a 7‑year period. We recorded 
empirical and definitive antibiotic therapies and susceptibility of causative pathogens. Amoxicillin, amoxicillin/clavula‑
nate (A/C) susceptibilities as well as amikacin susceptibility of A/C‑resistant strains were recorded.
Results:  From January 2007 to March 2014, 391 patients were included in the study. Empirical 3GCs were used in 
215 patients (55%). Among 267 patients with microbiologically documented CAP (68%), 241 received a beta‑lactam 
as definitive therapy, and of those, 3CGs were chosen for 43 patients (18%). Amoxicillin or A/C was active against iso‑
lated pathogens in 159 patients (66%), while 39 patients (16%) required a beta‑lactam with a broader spectrum than 
3GCs. Ninety‑four per cent of A/C‑resistant strains were amikacin susceptible.
Conclusions:  In ICU patients with CAP, 3GCs given on an empirical basis are changed, according to microbiological 
documentation, for another beta‑lactam in 82% of cases especially to A/C in the absence of resistance risk factor. In 
patients evidencing risk factors for A/C‑resistant strains infection, 3GCs or antipseudomonal beta‑lactams including 
carbapenem associated with amikacin in the most severe patients seem a relevant empirical antibiotic therapy. This 
strategy could decrease 3GCs’ use.
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Background
Community-acquired pneumonia (CAP) is a major cause 
of hospitalization and death worldwide [1, 2]. CAP is the 
leading infectious cause for admission in the intensive 
care unit (ICU) and one of the most common causes of 
sepsis, severe sepsis and septic shock [3, 4]. Guidelines 
published in 2006 by the French Intensive Care Soci-
ety (SRLF) and the French Infectious Diseases Soci-
ety (SPILF) [5] recommended a non-antipseudomonal 
third-generation cephalosporin (3GC, as ceftriaxone or 
cefotaxime) in combination with either a macrolide or 
a fluoroquinolone for empirical treatment of patients 
with severe CAP who require ICU admission. Since the 
publication of those recommendations, a sharp increase 
in 3GCs prescription has been observed, with a 58% 
increase in ceftriaxone use in France between 2008 and 
2013 (French National Institute for Public Health Surveil-
lance, RAISIN) [6]. Between 2003 and 2012, the incidence 
of third-generation cephalosporin-resistant strains, espe-
cially extended-spectrum beta-lactamases-producing 
Enterobacteriaceae (ESBLEs), increased from 0.17 to 0.48 
per 1000 hospitalization days [7].
Furthermore, the increased incidence of ESBLEs pro-
motes the use of carbapenems, which in turn could 
increase the risk of emergence and spreading of carbap-
enem-resistant strains. A restricted use of 3GCs could 
therefore be warranted [9], as it might provide a possible 
strategy to decrease incidence of 3GCs’ resistance [10]. 
Thus, the aim of our study was to assess whether the use 
of 3GCs in patients with CAP who require ICU admis-
sion was justified based on the microbiologically identi-
fied causative pathogen and its susceptibility pattern.
Methods
The study was conducted in a 670-bed tertiary teaching 
hospital in Paris, France. We retrospectively reviewed 
medical records of all consecutive adult patients who 
required ICU admission between January 2007 and 
March 2014 for acute respiratory failure. Pneumonia 
was diagnosed with the following criteria: a new alveo-
lar, interstitial or alveolo-interstitial opacity on chest 
radiography, associated with at least two of the following: 
cough, sputum production, temperature above 38  °C or 
below 35  °C, and auscultatory findings consistent with 
pneumonia or dyspnoea. To be considered a community-
acquired pneumonia, symptoms had to develop in the 
community or within the first 48 h after hospital admis-
sion [11–13]. Patients were admitted to the ICU from the 
emergency department or directly from the pre-hospital 
emergency medical team. The institutional review board 
of our institution approved the study.
For each patient included in the study, the follow-
ing parameters were recorded: age, sex, underlying 
comorbidities (chronic lung disease, hypertension, dia-
betes, chronic liver disease, heart failure, chronic renal 
disease, HIV infection, ongoing solid cancer or blood 
cancer), SAPS II score, mechanical ventilation use, intra-
venous vasopressors administered for septic shock and 
ICU mortality.
A pathogen was considered causal for CAP after a com-
prehensive and critical appraisal of clinical and micro-
biological data. The microbiological diagnostic workup 
for all patients included: blood cultures obtained upon 
admission and before antibiotic administration, expec-
torated sputum sample in patients able to cough or blind 
endotracheal aspirations in patients mechanically venti-
lated. A broncho-alveolar lavage through fibroscopy was 
performed if others means were deemed unsuccessful. 
Respiratory samples were analysed for Gram staining ini-
tially and after 48 h of culture. According to international 
guidelines, immunochromatographic tests for detection 
of  Streptococcus pneumoniae and Legionella pneumoph-
ila serogroup 1 antigen in urine were also performed [5]. 
The addition of PCR virus detection on lower respiratory 
samples or nasal–pharyngeal swabs (e.g. specific influenza 
PCR testing during the flu-season or respiratory virus 
PCR panel), or direct detection and quantitative PCR 
assessment of Pneumocystis jirovecii on broncho-alveolar 
fluid in patients with underlying immunosuppression was 
left at the discretion of the attending intensivist.
As per French guidelines, at our institution the com-
bination of ceftriaxone or cefotaxime with either a 
macrolide or a fluoroquinolone is used as empirical treat-
ment of patients with severe CAP requiring ICU admis-
sion. Then, as suggested by internal protocols, empiric 
antimicrobial therapy would be reassessed after 48  h 
by attending physicians and adjusted according to the 
microbiological cultures, if available. The most narrow-
spectrum antibiotic would be used as the definitive ther-
apy based on antimicrobial susceptibility results based on 
the antibiogram diameter inhibition and switched to the 
oral route as soon as possible. If pneumococcal pneumo-
nia were documented, the association of a beta-lactam 
and a macrolide would be maintained for the first 3 days 
[14] and then a beta-lactam (usually amoxicillin) would 
be maintained alone thereafter. If all cultures would 
remain negative in a patient having received any antibi-
otic before microbiological samples, the empiric therapy 
would be switched to oral pristinamycin. However, spe-
cial attention would be paid to the direct examination of 
the sputum specimen in those patients, as the presence of 
typical Gram stain aspects (e.g. Gram-positive diplococci 
or numerous Gram-negative bacilli) might modify the 
choice of definitive therapy. In general, fluoroquinolones 
use was discouraged except in case of confirmed severe 
legionellosis [15].
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The appropriateness of the 3GCs utilization was 
assessed in patients with microbiologically documented 
pneumonia, based on the susceptibility of the identified 
pathogens. Since Infectious Diseases Society of America/
American Thoracic Society Consensus Guidelines rec-
ommend 3GC or combination of amoxicillin/β-lactamase 
inhibitor in case of severe CAP [11], special attention was 
paid to amoxicillin/clavulanate (A/C) susceptibility. The 
empirical use of 3GCs was therefore classified as:
  • Unjustified when the pathogen was susceptible to 
amoxicillin or amoxicillin/clavulanate (A/C);
  • Appropriate when the pathogen was resistant to 
amoxicillin/clavulanic acid and susceptible to non-
antipseudomonal 3GCs;
  • Insufficient when the pathogen was resistant to both 
amoxicillin/clavulanate and non-antipseudomonal 
3GCs and required a broader-spectrum beta-lactam.
In patients presenting with CAP exhibiting A/C-resistant 
strains, we revised the charts to explore the presence of 
underlying comorbidities previously reported as risk fac-
tors for resistant pathogens [16] (e.g. chronic lung dis-
ease, hypertension, diabetes, chronic liver disease, heart 
failure, renal failure, HIV infection, stroke, ambulatory 
status, previous antibiotic treatment and progressive can-
cer). In those patients, we assessed the susceptibility to 
aminoglycosides (amikacin and gentamicin).
Statistical analysis
Data are presented as numbers and percentages for cate-
gorical variables and mean ± standard deviation (SD) for 
continuous variables. Comparison between groups was 
made using Pearson’s Chi-squared test. P values <0.05 
indicated statistical significance. Odds ratios for risk 
factors for A/C resistance were determined by logistic 
regression. An univariable analysis was first performed, 
and variables showing association with A/C resistance 
(P < 0.15) were included in a multivariate analysis, to cal-
culate odds ratios. All analyses were performed using R 
2.11.1 statistical package.
Results
Between January 2007 and March 2014, 7676 patients 
were admitted in the ICU. Out of 1071 patients hospital-
ized in the ICU for acute respiratory failure, a final diag-
nosis of CAP was made in 391 patients (Fig. 1).
Of these 391 patients (55% male, mean age: 
65  ±  19  years, SAPS II score of 47  ±  22), 172 (44%) 
required mechanical ventilation and 107 (27%) received 
vasopressors. Overall mortality during the ICU stay was 
18% (73 patients). Patients’ characteristics are presented 
in Table 1.
The initial empiric antibiotic therapy consisted in a mon-
otherapy in 53 patients (13%), a bitherapy in 312 patients 
(80%) and a tritherapy in 21 patients (5%). The bitherapies 
consisted in beta-lactam and macrolide (n =  277), beta-
lactam and metronidazole (n  =  34) and sulphonamides 
and macrolide (n = 1). The beta-lactams more frequently 
used were: a non-antipseudomonal 3GC in 215 patients 
(55%) and amoxicillin/clavulanate in 75 patients (19%) 
(Table  2). Macrolides were empirically prescribed in 277 
patients (70%). Oseltamivir was associated with antibiotic 
therapy on an empirical basis in 23 patients.
Microbiologically proven community‑acquired pneumonia
A causative pathogen was identified in 267 patients (68%) 
(Table  3). Streptococcus pneumoniae and Haemophilus 
influenzae were the most frequent pathogens, identified 
in 43.1 and 17.6% of cases, respectively.
Among the 267 patients with microbiologically proven 
CAP, 241 were given a beta-lactam alone as a definitive 
therapy (Table  4). In these patients, the empirical pre-
scription of 3GCs was unjustified in 159 patients (66%) 
and was changed for amoxicillin/clavulanate (n  =  70), 
amoxicillin (n =  87) or oxacillin (n =  2). The empirical 
3GC’s prescription was appropriate and continued in 43 
patients (18%) and insufficient in 39 patients (16%) in 
whom a broader-spectrum beta-lactam was required for 
definitive therapy. Finally, in patients with documented 
pneumonia requiring beta-lactam, non-antipseudomonal 
3GCs prescribed on an empirical basis were justified in 
less than a fifth of patients (Fig. 2).
No pneumococcal strain exhibited resistance to 
amoxicillin. Among H influenza strains, 43% were fully 
amoxicillin susceptible and 36% were amoxicillin resist-
ant and A/C susceptible, whereas 21% were A/C resist-
ant and cefotaxime susceptible. All Haemophilus strains 
were susceptible to spiramycin. Resistance to cefotaxime 
was mainly observed in non-fermenting Gram-negative 
bacilli. All patients with Pseudomonas aeruginosa-associ-
ated CAP had at least one of the specific risk factor previ-
ously defined in French guidelines [17].
Resistance to amoxicillin/clavulanate was observed in 
82 patients and was more frequent among patients with 
comorbidities (Table  5). In the multivariable analysis, 
variables significantly associated with resistance to amox-
icillin/clavulanate were chronic lung disease [OR 1.9 
(95% CI 1–3.6)], cancer [OR 4.5 (95% CI 2.0–9.8)], previ-
ous antibiotic therapy [OR 2.7 (95% CI 1.3–5.9)], limited 
autonomy [OR 2.9 (95% CI 1.0–8.2) and stroke [OR 0.1 
(95% CI 0.0–0.9)].
Among the 82 pathogens resistant to amoxicillin/cla-
vulanate, 18 strains (22%) were resistant to gentamicin, 
whereas five strains (6%) were resistant to both gen-
tamicin and amikacin.
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Discussion
In our retrospective study, we evaluated the efficacy 
and relevance of the chosen empirical antibiotic therapy 
especially non-antipseudomonal 3GCs in the light of the 
microbiologically identified pathogens and their suscepti-
bility result. To assess whether 3GCs were really justified, 
we focused on CAP with microbiological documentation, 
which required definitive beta-lactam therapy. These 
infections were separated into three groups according 
to whether 3GCs appeared unjustified (pathogen sus-
ceptible either to amoxicillin or amoxicillin/clavulanate), 
appropriate (pathogen cefotaxime susceptible and resist-
ant to amoxicillin/clavulanate) or insufficient (pathogen 
resistant to both amoxicillin/clavulanate and non-antip-
seudomonal 3GCs and requiring a broader-spectrum 
beta-lactam).
In the present study, 3GCs were the second most 
frequent empirical antibiotic used for severe CAP 
after macrolides (53 and 70%, respectively). This is in 
agreement with French guidelines [5]. Streptococcus 
pneumoniae and Haemophilus influenzae remain, as pre-
viously observed [18–22], the most frequent bacterial 
species causing CAP. These two pathogens accounted for 
60% cases of documented pneumonias. These pathogens 
are most often highly susceptible to narrow-spectrum 
β-lactams such as amoxicillin or amoxicillin/clavulanate 
[20], except for some H. influenzae isolates. In the pre-
sent studies, 10 H influenzae strains (21%) were amoxicil-
lin/clavulanate resistant, but all were susceptible to both 
cefotaxime and spiramycin.
The group of unjustified third-generation cephalo-
sporin prescription is the most important with 66% 
(159) of patients with documented infection; in this 
group, treatment with amoxicillin or amoxicillin/clavu-
lanate would have been sufficient. Appropriate 3GC’s 
prescription was observed in only 18% (43 patients) of 
our cohort. Finally, the group in which third-generation 
cephalosporin use appeared insufficient represents 16% 
7676 patients admitted to the ICU from January 2007 to March 2014
6605 were excluded
Admitted to ICU for other 
diagnosis than acute 
respiratory failure
1071 patients were admitted to ICU for acute respiratory failure
680 were excluded
Admitted to ICU for
-HAP: 439
-Other nosocomial ARF: 46
-COPD exacerbation: 65




391 patients with CAP included in the analysis
Fig. 1 Flow chart of patients included in the analysis. HAP hospital‑associated pneumonia, ARF acute respiratory failure, COPD chronic obstructive 
pulmonary disease
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(39) of patients, meaning that in these patients a beta-
lactam with a broader spectrum than 3GCs would have 
been required.
These results suggest that the use of third-generation 
cephalosporins as an empiric beta-lactam for treatment 
of severe community-acquired pneumonia admitted to 
the ICU is a perfectly tailored antibiotic therapy in only 
one out of five patients. Most of the time, a narrower-
spectrum beta-lactam might be preferred. The amoxi-
cillin/clavulanate combination would be a satisfactory 
alternative to 3GCs against two-thirds of overall recov-
ered pathogens. Moreover, non-antipseudomonal 3GC 
spectrum appears insufficient in one out of six patients 
with CAP requiring beta-lactam.
In a second part of the study, we sought to delineate 
patients for whom amoxicillin/beta-lactamase inhibitor 
would be insufficient and who would require a broader-
spectrum beta-lactam. For that, we assessed the presence 
or absence of risk factors associated with colonization/
infection with resistant strains previously reported [21]. 
We found that chronic lung disease, ongoing cancer, non-
ambulatory status and previous antibiotic therapy were 
significantly associated with amoxicillin/clavulanate-
resistant strains.
Table 1 Patients’ characteristics
Characteristics N %
Sex (male) 215 55.0
Age 65 ± 19
IGSII 47 ± 22
Chronic lung disease 119 30.4
HTA 142 36.3
Diabetes mellitus 57 14.6
Congestive heart failure 43 11.0
Chronic liver disease 41 10.4
Chronic renal disease 23 5.9
Stroke 19 4.9
Progressive cancer 22 5.6
Blood cancer 37 9.5
HIV 20 5.1
Other causes of immunosuppression 8 2.0
Mechanical ventilation 172 44.0
Catecholamines 107 27.3
Acute renal failure 16 4.1
Renal replacement therapy 1 0.3
Mortality 73 18.6
Table 2 Anti-infective therapies administered on  an 
empirical basis to  the 391 patients with  community-
acquired pneumonia
Empirical antibiotic therapies N (%)
Macrolides 277 (71)












Table 3 Distribution of  pathogens identified in  267 
patients with  documented community-acquired pneumo-
nia
The total count of pathogens exceeds the total number of documented 
pneumonia since 33 pneumonias were caused by two pathogens
Microbiological strains n (%)
Streptococcus pneumonia 115 (43.1)
Haemophilus influenza 47 (17.6)
Moraxella catarrhalis 4 (1.5)
Legionella pneumophila 7 (2.6)
Mycoplasma pneumoniae 1 (0.3)
Enterobacteriaceae
 Escherichia coli 22 (8.2)
 Klebsiella pneumoniae 15 (5.6)
 Klebsiella oxytoca 3 (1.1)
 Serratia marcescens 4 (1.5)
 Enterobacter cloacae 4 (1.5)
 Morganella morganii 3 (1.1)
 Proteus mirabilis 2 (0.7)
 Hafnia alvei 1 (0.3)
 Enterobacter aerogenes 1 (0.3)
Non‑fermenting Gram‑negative bacteria
 Pseudomonas aeruginosa 22 (8.2)
 Stenotrophomonas maltophilia 2 (0.7)
 Acinetobacter baumannii 1 (0.3)
Methi‑S Staphylococcus aureus 18 (5.7)
Methi‑R Staphyloccocus aureus 3 (1.1)
Corynebacterium 3 (1.1)
Fusobacterium other 1 (0.3)
Neisseiria sp. other 1 (0.3)
Streptococcus anginosus other 1 (0.3)
Streptococcus milleri other 2 (0.3)
Pneumocystis jirovecii 11 (4.1)
Viruses
 H1N1 influenzae 4 (1.5)
 Adenovirus 1 (0.3)
Mycobacterium tuberculosis 1 (0.3)
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These amoxicillin/clavulanate-resistant isolates (mainly 
Pseudomonas aeruginosa, non-fermenting Gram-neg-
ative bacilli and several Enterobacteriaceae) were most 
of the time sensitive to amikacin (94%), suggesting that 
this antibiotic could be considered in patients with risk 
factors for infection with an amoxicillin/clavulanate non-
susceptible pathogen.
Prior use of 3CGs has been identified as a risk factor 
for infections caused by ESBL-producing Enterobacte-
riaceae [8, 23, 24]. Recent experiments report a decrease 
in ESBLEs emergence following decrease in cephalo-
sporins use [10]. These data support, when possible, a 
decrease in the use of 3CGs to control ESBL-producing 
Enterobacteriaceae spreading. According to our results, 
amoxicillin/clavulanate could be proposed as an alterna-
tive beta-lactam for severe CAP in patients without risk 
factors for amoxicillin/clavulanate resistance. This situa-
tion (absence of A/C resistance risk factor) is observed in 
55% of patients.
Such a strategy could contribute to limit the 3GCs use 
and then probably the emergence of extended-spectrum 
beta-lactamases (ESBLs). It is important to note that 
conversely to French recommendations, amoxicillin/
beta-lactamase inhibitor is proposed as a possible first-
line empirical beta-lactam for ICU patients with CAP in 
North American [11] and British [25] guidelines. Reduc-
ing the use of third-generation cephalosporins for CAP is 
already suggested in the emergency department [26].
Among patients with risk factors for amoxicillin/cla-
vulanate resistance, strains encountered are very similar 
to those observed in patients with healthcare-associated 
pneumonia, and even this is still debated, to strains iden-
tified in patients with ventilator-associated pneumonia 
and/or hospital-acquired pneumonia [16–27]. The lat-
ter patients should receive at least 3GCs for empirical 
treatment and antipseudomonal beta-lactam (piperacil-
lin/tazobactam, cefepime, ceftazidime) or carbapenem 
associated with an aminoglycoside for the most severe 
Table 4 Empiric and  definitive beta-lactams given  to 241 
patients with documented pneumonia requiring at least a 
beta-lactam
Beta‑lactam n (%)
Non‑antipseudomonal 3GC unjustified 159 (65.9)
 Amoxicillin 87 (36.1)
 Amoxicillin/clavulanate 70 (29)
 Oxacillin 2 (0.8)
Non‑antipseudomonal 3GC appropriate 43 (17.8)
Non‑antipseudomonal 3GC inappropriate 39 (16.2)
 Piperacillin/tazobactam 16 (6.7)
 Ticarcillin 9 (3.7)
 Carbapenem 7 (2.9)
 Ceftazidime 3 (1.2)
 Tazocillin/clavulanate 2 (0.8)
 Cefepime 1 (0.4)







3GCs insuficient 3GCs justiied 3GCs injustiied
Fig. 2 Relevance of third‑generation cephalosporins given on an 
empirical basis to patients with documented community‑acquired 
pneumonia and requiring at least a beta‑lactam
Table 5 Univariable and  multivariable analysis of  comor-
bidities associated with infection due to amoxicillin/clavu-
lanate non-susceptible
a At least 2 days in the last 90 days
b Non-ambulatory status was defined as being bedridden or using a wheelchair 
because of difficulty walking
Comorbidities Univariable analysis Multivariable 
analysis
OR (95% CI) P value OR (CI 95%) P value
Arterial hypertension 1.3 (0.7–2.2) 0.40
Chronic lung disease 1.7 (0.9–3.1) 0.09 1.9 (1.0–3.6) 0.05
Chronic renal failure 1.6 (0.4–6.0) 0.52
Chronic liver disease 0.7 (0.3–1.6) 0.36




Diabetes mellitus 1.0 (0.4–2.4) 0.97
Cancer 4.3 (2.1–9.1) 0.001 4.5 (2.0–9.8) 0.04
Stroke 0.2 (0.0–1.2) 0.07 0.1 (0.0–0.9) 0.03
Nursing home/non‑
ambulatoryb
2.1 (0.9–5.0) 0.11 2.9 (1.0–8.2) 0.04




Hospitalizationa 1.6 (0.8–3.4) 0.23
Antibiotic during last 
90 days
2.7 (1.3–5.6) 0.01 2.7 (1.3–5.9) 0.01
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patients. Amikacin appears in the present study more 
frequently efficient than gentamicin.
The present study has, however, several limitations. 
First, whereas some of the observed data are similar 
to previously published results, the present study is a 
single-centre retrospective study with a moderate size 
population. Thus, these results should be interpreted 
cautiously and confirmed in a larger population. Sec-
ond, our approach relies on an extensive infectious 
workup including invasive procedures, which is a 
strategy not supported by current guidelines in non-
immunocompromised patients. Nevertheless, owing to 
significant increase in antibiotic resistance and to the 
necessity of a relevant antimicrobial stewardship, an 
aggressive diagnostic approach dedicated to increase 
the rate of microbiological identification in order to 
use the antibiotic therapy with the narrowest spectrum 
seems mandatory.
Conclusion
In ICU patients with documented community-acquired 
pneumonia who require definitively a beta-lactam, we 
observed that 3GCs are most of the time an unjustified 
or insufficient antibiotic therapy. Based on the present 
retrospective analysis, a narrower-spectrum beta-lactam 
antibiotic with amoxicillin/clavulanate combined with a 
macrolide could replace 3GCs as empirical antibiotics for 
severe CAP in patients without risk factors for amoxicil-
lin/clavulanate resistance, i.e. chronic lung disease, ongo-
ing cancer, non-ambulatory status and antibiotic therapy 
during the previous 90 days. In patients with risk factors 
for amoxicillin/clavulanate resistance, 3GCs, antipseu-
domonal beta-lactam including carbapenem associated 
with amikacin in the most severe patients seems a rele-
vant empirical antibiotic therapy. This strategy could pro-
mote a decrease in 3GCs’ consumption.
Abbreviations
3GC: third‑generation cephalosporin; ESBL: extended‑spectrum beta‑lacta‑
mase; ICU: intensive care unit; CAP: community‑acquired pneumonia; HCAP: 
healthcare‑associated pneumonia; A/C: amoxicillin/clavulanate.
Authors’ contributions
GH took part to the conception and design of the study, acquired the data, 
had major input in the data analysis and wrote the draft of the manuscript. JT 
took part to the design of the study and extracted the microbiological data. 
PYB took part to the design of the study and conducted uni‑ and multivari‑
able analysis and had major input in the data analysis. VD contributed to data 
analysis, and GL contributed to database elaboration. CP, SB, NB, JLB, AG and 
HAO took part to the design of the study and contributed to data analysis. EM 
conceptualized and designed the study, contributed to database elaboration, 
had major input in data interpretation and had major input in manuscript 
writing and revision. All authors read and approved the final manuscript.
Author details
1 Service de Réanimation Médicale, Hôpital Saint‑Antoine, Assistance 
Publique‑Hôpitaux de Paris, 184 rue du faubourg Saint‑Antoine, 75571 Paris, 
France. 2 Microbiologie, Hôpital Saint‑Antoine, Assistance Publique‑Hôpitaux 
de Paris, Paris, France. 3 Institut Pierre‑Louis d’Epidémiologie et de Santé 
Publique, U 1136, Inserm, 75012 Paris, France. 4 UPMC Univ Paris 06, Sorbonne 
Universités, Paris, France. 5 Réanimation Polyvalente, HP Claude Galien, 
91480 Quincy‑sous‑Sénart, France. 
Competing interests
The authors declare that they have no competing interests.
Availability of data and materials
Medical files can be found in our ICU 4D fusion software database. Micro‑
biological data can be found in the data base of our hospital microbiology 
department.
Ethical approval and consent to participate
The institutional review board of our hospital authorized this retrospective 
analysis. All patients or next of kin gave their consent for the data obtained 
during their ICU stay to be retrospectively analysed.
Received: 6 October 2016   Accepted: 15 March 2017
References
 1. Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community‑
acquired pneumonia in adults in Europe: a literature review. Thorax. 
2013;68:1057–65.
 2. Musher DM, Thorner AR. Community‑acquired pneumonia. N Engl J Med. 
2014;371:1619–28.
 3. Walden AP, Clarke GM, McKechnie S, Hutton P, Gordon AC, Rello J, et al. 
Patients with community acquired pneumonia admitted to European 
intensive care units: an epidemiological survey of the GenOSept cohort. 
Crit Care. 2014;18:R58. doi:10.1186/cc13812.
 4. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al. 
Understanding the inflammatory cytokine response in pneumonia and 
sepsis: results of the Genetic and Inflammatory Markers of Sepsis (Gen‑
IMS) Study. Arch Intern Med. 2007;167:1655–63.
 5. Société de Réanimation de Langue Française. 15th consensus conference 
about management of lower respiratory tract infections in immunocom‑
petent adult. Med Mal Infect. 2006;36:235–44.
 6. Desenclos JC, RAISIN Working Group. RAISIN—a national programme for 
early warning, investigation and surveillance of healthcare‑associated 
infection in France. Euro Surveill. 2009;14:1–8.
 7. Carbonne A, Arnaud I, Maugat S, Marty N, Dumartin C, Bertrand X, et al. 
National multidrug‑resistant bacteria (MDRB) surveillance in France 
through the RAISIN network: a 9 year experience. J Antimicrob Chem‑
other. 2013;68:954–9.
 8. Gbaguidi‑Haore H, Dumartin C, L’Hériteau F, Péfau M, Hocquet D, Roques 
AM, et al. Antibiotics involved in the occurrence of antibiotic‑resistant 
bacteria: a nationwide multilevel study suggests differences within 
antibiotic classes. J Antimicrob Chemother. 2013;68:461–70.
 9. Carlet J. Ten tips on how to win the war against resistance to antibiotics. 
Intensive Care Med. 2015;41:899–901.
 10. Livermore DM, Hope R, Reynolds R, Blackburn R, Johnson AP, Woodford 
N, et al. Declining cephalosporin and fluoroquinolone non‑susceptibility 
among bloodstream Enterobacteriaceae from the UK: links to prescribing 
change? J Antimicrob Chemother. 2013;68:2667–74.
 11. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean 
NC, et al. Infectious Diseases Society of America/American Thoracic Soci‑
ety consensus guidelines on the management of community‑acquired 
pneumonia in adults. Clin Infect Dis. 2007;44:27–72.
 12. Johnstone J, Majumdar SR, Marrie TJ. The value of prognostic indices for 
pneumonia. Curr Infect Dis Rep. 2008;10:215–22.
 13. Lim WS. Defining community acquired pneumonia severity on presenta‑
tion to hospital: an international derivation and validation study. Thorax. 
2003;58:377–82.
 14. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal 
SM, et al. Surviving sepsis campaign: international guidelines for 
Page 8 of 8Hariri et al. Ann. Intensive Care  (2017) 7:35 
management of severe sepsis and septic shock, 2012. Intensive Care 
Med. 2013;39:165–228.
 15. Bretonnière C, Leone M, Milési C, Allaouchiche B, Armand‑Lefevre 
L, Baldesi O, et al. Strategies to reduce curative antibiotic therapy 
in intensive care units (adult and paediatric). Intensive Care Med. 
2015;41:1181–96.
 16. Shindo Y, Ito R, Kobayashi D, Ando M, Ichikawa M, Goto Y, et al. Risk factors 
for drug‑resistant pathogens in community‑acquired and healthcare‑
associated pneumonia. Am J Respir Crit Care Med. 2013;188:985–95.
 17. Chidiac C, la Société de pathologie infectieuse de langue Française. 
Antibiothérapie par voie générale dans les infections respiratoires 
basses de l’adulte. Pneumonie aiguë communautaire. Exacerbations de 
bronchopneumopathie chronique obstructive. Médecine Mal Infect. 
2011;41:221–8.
 18. Bohte R, van Furth R, van denBroek PJ. Aetiology of community‑acquired 
pneumonia: a prospective study among adults requiring admission to 
hospital. Thorax. 1995;50:543–7.
 19. The British Thoracic Society Research Committee and The Public Health 
Laboratory Service. The aetiology, management and outcome of severe 
community‑acquired pneumonia on the intensive care unit. Respir Med. 
2012;86:7–13.
 20. Woodhead M. Community‑acquired pneumonia in Europe: causative 
pathogens and resistance patterns. Eur Respir J. 2002;36(Suppl):20–7.
 21. Moine P, Vercken JB, Chevret S, Gajdos P. Severe community‑acquired 
pneumonia. Etiology, epidemiology, and prognosis factors. French Study 
Group for Community‑Acquired Pneumonia in the Intensive Care Unit. 
Chest. 1994;105:1487–95.
 22. Welte T, Torres A, Nathwani D. Clinical and economic burden of commu‑
nity‑acquired pneumonia among adults in Europe. Thorax. 2012;67:71–9.
 23. Patterson JE. Antibiotic utilization: is there an effect on antimicrobial 
resistance? Chest. 2001;119(suppl):426–30.
 24. Trecarichi EM, Cauda R, Tumbarello M. Detecting risk and predicting 
patient mortality in patients with extended‑spectrum β‑lactamase‑
producing Enterobacteriaceae bloodstream infections. Future Microbiol. 
2012;7:1173–89.
 25. Lim WS, Baudouin SV, George RC, et al. BTS guidelines for the manage‑
ment of community acquired pneumonia in adults: update. Thorax. 
2009;64(Suppl 3):1–55.
 26. Goffinet N, Lecadet N, Cousin M, Peron C, Hardouin JB, Batard E, et al. 
Increasing use of third‑generation cephalosporins for pneumonia in the 
emergency department: may some prescriptions be avoided? Eur J Clin 
Microbiol Infect Dis. 2014;33:1095–9.
 27. Khalil A, Metesky M, Klompas M, Muscedere J, Sweeney D, Palmer L, et al. 
Executive summary. Management of adults with hospital‑acquired and 
ventilator‑associated pneumonia: 2016 clinical practice guidelines by 
the Infectious Diseases Society of America and the American Thoracic 
Society. Clin Infect Dis. 2016;63:575–82.
